Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Antibody Targeting Neurotoxic Protofibrils
Links shared publicly online about this topic.
- 903total visits
Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Antibody Targeting Neurotoxic Protofibrils
Eisai Co., Ltd. (Headquarters: Tokyo, Japan, President & CEO: Haruo Naito, Eisai) announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody
View full resource at medicalnewstoday.com
Tags: Eisai
Most Recently Shared on September 2, 2010 at 10:00 pm By:
Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Antibody Targeting Neurotoxic Pr... http://mnt.to/3Jc4
Also Shared By:
Advertisement
MNT Alzheimer's News
@mnt_alzheimers
Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Antibody Targeting Neurotoxic Pr... http://mnt.to/3Jc4
1 year ago...